Compare TG Therapeutics Inc (TGTX) vs ProShares Ultra Semiconductors (USD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs ProShares Ultra Semiconductors — how do they compare? TG Therapeutics Inc trades at $54.77 (market cap $8.53B), while ProShares Ultra Semiconductors trades at $89.08. The key difference: TG Therapeutics Inc is trading nearer its 52-week high, ProShares Ultra Semiconductors nearer its low. Which is the better fit depends on your goals.
| TGTX | USD | |
|---|---|---|
Market Cap | $8.53B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $59.06 | $113.53 |
52-Week Low | $26.94 | $43.19 |
Enterprise Value | $8.74B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
USD stock trades at $89.70, up 1.01% with bullish technical signals from moving averages. The company announced a dividend of $0.14 per share scheduled for June 2026. Technical indicators show strong support at $88 and resistance at $92, with RSI levels in neutral territory suggesting balanced momentum.
The stock shows technical strength but lacks current fundamental data for comprehensive valuation. The upcoming dividend provides income appeal, though investors face uncertainty without recent financial metrics. Market sentiment appears cautiously optimistic given the technical setup and corporate action.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About ProShares Ultra Semiconductors
USD is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Dow Jones U.S. Semiconductors™ Index. It is a tactical instrument designed for sophisticated traders looking to magnify short-term bullish views on the U.S. semiconductor industry, specifically focusing on large-cap leaders in the chip and equipment space.
Read more on USD →
